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http://dx.doi.org/10.1016/j.ccr.2013.10.003SUMMARYTargeted inactivation of Runx3 in mouse lung induced mucinous and nonmucinous adenomas and markedly
shortened latency of adenocarcinoma formation induced by oncogenic K-Ras. RUNX3 was frequently inac-
tivated in K-RAS mutated human lung adenocarcinomas. A functional genetic screen of a fly mutant library
and molecular analysis in cultured cell lines revealed that Runx3 forms a complex with BRD2 in a K-Ras-
dependent manner in the early phase of the cell cycle; this complex induces expression of p14ARF/p19Arf
and p21WAF/CIP. When K-Ras was constitutively activated, the Runx3-BRD2 complex was stably maintained
and expression of both p14ARF and p21WAF/CIP was prolonged. These results provide a missing link between
oncogenic K-Ras and the p14ARF-p53 pathway, and may explain how cells defend against oncogenic K-Ras.INTRODUCTION
Lung adenocarcinoma (ADC) is the most common form of lung
cancer, and its incidence is increasing rapidly. Most lung ADCs
develop through a stepwise progression from atypical adenoma-
tous hyperplasia (AAH), to bronchio-alveolar carcinoma (BAC),
and finally to multiple types of invasive tumors including
mucinous and nonmucinous ADCs (Wistuba and Gazdar,
2006). K-RAS is one of the most frequently mutated oncogenes
in lung ADC patients, and approximately 76% of mucinous lung
ADCs have K-RAS mutations (Subramanian and Govindan,
2008). Mouse lung adenoma (AD) is considered to be equivalent
to human AAH and BAC.
Activation of K-Ras by intra-nasal infection of K-RasLSL-G12D/+
mice with adenovirus harboring Cre-recombinase (Adeno-Cre)Significance
Oncogenic K-Ras induces lung adenocarcinoma, and the p14A
known how the p14ARF-p53 pathway is activated by oncogenic
mation but not adenoma formation. Thus, our knowledge of tu
incomplete. Our results show that, in mice, Runx3 inhibits a
p14ARF-p53 pathway in a K-Ras-dependent manner. Restorat
cancer cell line activated the p14ARF-p53 pathway, ultimately le
edge regarding how cells are protected from forming adenom
Canleads to the development of nonmucinous lung AD, which pro-
gresses into ADC (Jackson et al., 2001; Kim et al., 2005a; Xu
et al., 2012). K-Ras activation in bronchio-alveolar stem cells
can initiate lung ADs/ADCs (Kim et al., 2005a), and nonmucinous
ADCs can arise from alveolar epithelial AT2 cells following K-Ras
activation (Xu et al., 2012). Nkx2-1, which is essential for pulmo-
nary differentiation (Minoo et al., 2007), inhibits the initiation of
mucinous lung ADC by oncogenic K-Ras (Maeda et al., 2012;
Snyder et al., 2013).
Oncogenic Ras induces premature senescence in primary
cells, except when its expression is accompanied by coincident
loss of tumor-suppressor activity, suggesting the existence of a
cellular defense mechanism against oncogenic insults (Palmero
et al., 1998; Efeyan and Serrano, 2007). Indeed, simultaneous
activation of oncogenic K-Ras and inactivation of p53 tumorRF-p53 pathway antagonizes this process. However, it is not
K-Ras, or why p53 inhibits malignant adenocarcinoma for-
mor suppression at the early stage of tumor development is
denoma formation and contributes to the activation of the
ion of RUNX3 in K-RAS-mutated human non-small-cell lung
ading to apoptosis. Our results fill the gap in current knowl-
as at the very early stages of that process.
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Figure 1. Runx3 Inactivation Leads to Induction of Lung ADs
(A) Schematic illustration of the Runx3flox allele.
(B and C) Images of Adeno-Cre-infected wild-type (WT) and Runx3f/f mouse lungs at 1, 2, or 4 months postinfection. Magnified images of the boxed regions are
shown on the right.
(legend continued on next page)
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Runx3 Suppresses K-Ras-Induced Lung Cancersuppressor in lung significantly accelerates the malignancy of
the resultant ADC (DuPage et al., 2009). The p14ARF-p53-
p21WAF/CIP pathway is considered to play a major role in cellular
defense against oncogenic Ras-induced tumor formation:
p14ARF (in mouse, p19Arf; hereafter ARF or Arf) is induced by
oncogenic Ras and stabilizes p53, which triggers the expression
of many apoptosis inducers and cell-cycle-inhibitory genes to
suppress aberrant cell growth (Levine, 1997; Efeyan and
Serrano, 2007; Kruse and Gu, 2009). Although ARF and
p21WAF/CIP (hereafter, p21) are undoubtedly critical components
of the p53 pathway, these proteins also play p53-independent
roles in tumor suppression (Abbas and Dutta, 2009; Sherr,
2006). Importantly, restoration of p53 inhibits growth of ADC
but not AD (Feldser et al., 2010; Junttila et al., 2010). The mech-
anisms by which the ARF-p53 pathway is activated by onco-
genic Ras and cells defense against development of lung AD
have not yet been fully elucidated.
The RUNX family of transcription factors plays a pivotal role in
normal development and neoplasia. RUNX1 is essential for
hematopoiesis and is often mutated in leukemia; likewise,
RUNX2 is required for osteogenesis, and mutations in this
gene are associated with bone disease (Lund and van Lohuizen,
2002). All members of the RUNX family genes induce a senes-
cence-like growth arrest in primary MEFs in response to onco-
genic Ras (Kilbey et al., 2008). RUNX3 functions as a tumor
suppressor and is frequently inactivated by DNA hyper-methyl-
ation in the stomach, bladder, colon, and lung (Ito et al., 2008;
Kim et al., 2005b; Lee et al., 2010; Li et al., 2002; Weisenberger
et al., 2006). RUNX3 is frequently inactivated in human AAH/
BAC, and Runx3 is downregulated in urethane-induced mouse
lung AD (Lee et al., 2010; Licchesi et al., 2008), suggesting that
RUNX3 inactivation is an early event in lung tumorigenesis. In
this study, we analyzed the role of Runx3 and the underlying
molecular mechanisms in the cellular defense against oncogenic
K-Ras-induced lung tumorigenesis.
RESULTS
Disruption of Runx3 Results in the Development
of Endobronchial Papillary Structures and AD
To understand the role of Runx3 in postnatal differentiation of
lung epithelial cells, we disrupted Runx3 2 months after birth
by intranasally infecting Runx3f/f mice with Adeno-Cre (2.5 3
107 PFU; Figure 1A), as previously described (DuPage et al.,
2009). Microscopic analysis revealed extensive micropapillary
growth of the bronchiolar epithelium in infected Runx3f/f mice
as early as 1 month post-infection (Figure 1B). At 2 months post-
infection, micropapillary cells had grown out and formed endo-
bronchial papillary structures (Figure 1B); however, the alveolar
regions were grossly normal. These results suggest that post-
natal disruption of Runx3 in mouse lung leads to hyper-prolifer-
ation of bronchiolar epithelial cells.(D) Hematoxylin and eosin staining (H&E) and double-immunofluorescence stai
4 months postinfection. Themerged image is also shown. Strongly positive, positi
orange, and yellow staining, respectively. Magnified images of the boxed bronch
(E) Immunofluorescence staining (white, PCNA; red, CC10; green, SP-C; blue, D
infection. The merged image is shown. Magnified images of the boxed regions a
See also Figure S1.
CanAt 4 months postinfection, the lungs developed multiple tu-
mors (Figure 1C); the lack of nuclear pleomorphism and the
low frequency of mitotic figures suggested that the tumors
were ADs. Nearly all the ADs developed in Adeno-Cre-infected
Runx3f/fmouse lungs were associated with endobronchial papil-
lary structures at the early stage (Figure S1A available online).
InfectedRunx3f/fmice developed two distinct types of ADs: one
containing abundant mucin-producing goblet cells (mucinous),
andtheothercontainingfewgobletcells (nonmucinous;Figure1C).
These two types are reminiscent of the mucinous and non-
mucinous AAHs/BACs seen in human lung tumors (Travis et al.,
2004). The numbers of mucinous and non-mucinous ADs that
developed in Runx3-inactivated mice were nearly the same; we
also observed mixed mucinous and non-mucinous ADs, although
thesewere rare. Approximately 20%of infectedRunx3f/fmicedied
by 1 year and the ADs did not progress into ADCs.
Disruption of Runx3 Results in the Generation of SP-C+/
CC10+ Cells
Because Runx3 inactivation induced lung ADs, which are asso-
ciated with bronchiolar micropapillary structures, we next inves-
tigated the role ofRunx3 in differentiation of bronchiolar epithelial
cells. Immunofluorescence analysis of Adeno-Cre-infected
Runx3f/f mouse lungs (4 months postinfection) using antibodies
specific for AT2 cells (SP-C) and Clara cells (CC10) revealed
that nearly all of the bronchiolar epithelial cells exhibiting micro-
papillary growth expressed both SP-C and CC10 (Figure 1D;
Figure S1B). The SP-C+/CC10+ cells formed endobronchial
papillary structures, which appeared to be extended into the
tumor masses of the ADs and strongly SP-C-positive cells ap-
peared at the BADJ (Figure 1D).
Detection of proliferating cells in Adeno-Cre-infected Runx3f/f
mouse lungs (4 months postinfection) using antibodies specific
for proliferating cell nuclear antigen (PCNA) revealed that a large
number of the SP-C+/CC10+ bronchiolar epithelial cells
expressed PCNA, whereas PCNA-expressing cells were very
rare in Adeno-Cre-infected WT mouse lung (Figure 1E). This
result confirmed that the Runx3-inactivated bronchiolar epithe-
lial cells are hyperproliferative.
Sox2 plays essential roles in lung development and is ex-
pressed in the proximal airways but not the alveoli of adult
mouse lung (Gontan et al., 2008). Analysis of the expression of
two bronchiolar epithelial cell markers, CC10 and Sox2, in the
mass of AD developed in Adeno-Cre-infected Runx3f/f mouse
lungs revealed that CC10 and Sox2 were highly expressed in
some regions of the ADs and these levels decreased gradually
as the distance from the core region increased (Figure S1C).
The Combination of Runx3 Inactivation and K-Ras
Activation Induces ADCs
To investigate the relationship between loss of Runx3 and
K-Ras-induced tumorigenesis, we crossed Runx3f/f andning (red, CC10; green, SP-C) of Adeno-Cre-infected Runx3f/f mouse lung at
ve, and weakly positive SP-C+/CC10+ cells are indicated by bright orange, dark
iolar (Br) and BADJ regions are shown below.
API) of Adeno-Cre-infected WT and Runx3f/f mouse lungs at 2 months post-
re shown below each panel.
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Figure 2. Combination of Runx3 Inactivation and K-Ras Activation Rapidly Induces Lung ADCs
(A) Schematic illustration of theK-RasLSL-G12D allele and survival curves for Adeno-Cre-infectedRunx3f/f,K-RasLSL-G12D/+, andRunx3f/f/K-RasLSL-G12D/+mice. The
median survival of infected K-RasLSL-G12D/+ mice and Runx3f/f/K-RasLSL-G12D/+ mice was 220 days and 79 days, respectively.
(B) Images of Adeno-Cre-infected K-RasLSL-G12D/+ mouse lungs. Magnified images of the boxed regions are shown on the right.
(legend continued on next page)
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Runx3 Suppresses K-Ras-Induced Lung CancerK-RasLSL-G12D/+mice (Jackson et al., 2001) to generate Runx3f/f/
K-RasLSL-G12D/+ mice, which were then infected with Adeno-Cre
via nasal inhalation. Infected K-RasLSL-G12D/+ mice began to die
120 days after infection (median survival, 220 days). In contrast,
infected Runx3f/f/K-RasLSL-G12D/+ mice began to die 60 days
after infection, and all of thesemice diedwithin 100 days (median
survival, 79 days; Figure 2A). The potent tumor-suppressor activ-
ity of Runx3 observed in this experiment is nearly equivalent to
that of p53, reported previously (DuPage et al., 2009).
All K-RasLSL-G12D/+ mice (n = 10) developed ADs at 2 months
postinfection and malignant ADCs at 4 months postinfection
(Figure 2B), as reported previously (Jackson et al., 2001). The
K-RasLSL-G12D/+ mice developed only nonmucinous lung ADs/
ADCs (Figure 2B). Runx3 is expressed at similar levels in
most bronchiolar and alveolar epithelial cells in WT mouse
lung (Lee et al., 2010). Consistent with the idea that loss of
Runx3 contributes to K-Ras-induced tumorigenesis, the level
of Runx3 expression was significantly lower than the level in
surrounding tissue in cells from nearly all tumors (24 out of 25
ADCs) developed in infected K-RasLSL-G12D/+ mouse lungs
(Figure 2C).
By contrast, all Runx3f/f/K-RasLSL-G12D/+ mice (n = 10) devel-
oped ADCs that exhibited nuclear pleomorphism and a high
frequency of mitotic figures by 2 months postinfection.
Runx3f/f/K-RasLSL-G12D/+ mice also developed both mucinous
and non-mucinous lung ADCs (Figure 2D; Figure S2A), suggest-
ing that each type represents the malignant form of the corre-
sponding type of AD that developed in the lungs of Runx3f/f
mice. Therefore, Runx3f/f and Runx3f/f/K-RasLSL-G12D/+ mice
are excellent models that closely recapitulate multiple types of
human lung AAHs/BACs and ADCs. Targeting of Runx3f/f and
K-RasLSL-G12D in the tumor mass was confirmed by PCR
(Figure S2B).
Double-immunostaining of ADCs in Adeno-Cre-infected
Runx3f/f/K-RasLSL-G12D/+ mouse lungs revealed an abundance
of cells expressing high levels of SP-C and CC10 within the
bronchiolar epithelium (Figure 2E). The grown-out endobronchial
papillary structures extended to the main body of the ADCs, and
exhibited a gradual increase of SP-C and a decrease of CC10 as
a function of their distance from the origin (Figure 2E).
RUNX3 Is Inactivated in K-RAS-Induced Human Lung
ADCs
Previously, we showed that RUNX3 is frequently inactivated by
downregulation or mislocalization in human lung ADCs (Lee
et al., 2010). Motivated by the findings described above, we
sought to determine whether RUNX3 is preferentially inactivated
in K-RAS-induced lung ADCs. To this end, we obtained 20
samples each of K-RAS-mutated, EGFR-mutated, and K-RAS/
EGFR-nonmutated human lung ADCs, and immunostained
them with two independent anti-RUNX3 antibodies, which
yielded essentially identical patterns of RUNX3 expression (Fig-
ure S3A). Only 8 of the 60 samples exhibited normal RUNX3(C) Runx3 expression detected using anti-Runx3 antibody (1E10) in Adeno-Cre-i
(D) Images of Adeno-Cre-infected Runx3f/f/K-RasLSL-G12D/+ mouse lungs. Magnifi
(E) H&E and double-immunofluorescence staining (red, CC10; green, SP-C) o
postinfection).
See also Figure S2.
Canexpression, and all of these were K-RAS/EGFR-nonmutated
ADCs (Figure 3A). All of the K-RAS- or EGFR-mutated lung
ADCs exhibited downregulation or mislocalized expression of
RUNX3 (Figures 3A and 3B).
The frequencies of p53 inactivation were 50%, 35%, and 35%
in K-RAS-mutated, EGFR-mutated, and nonmutated samples,
respectively, suggesting that p53 inactivation is not essential
for formation of K-RAS-induced human lung ADCs (Figure 3A).
Detailed information regarding the inactivation of K-RAS,
EGFR, p53, and RUNX3 in each case of ADC is provided in Fig-
ure S3B. These results indicate that RUNX3 inactivation is
closely associated with the formation of K-RAS-induced human
lung ADCs.
Runx3 Is Required for the Induction of Arf and p21
following Serum Stimulation and K-Ras Activation
Based on the observation that Runx3 inhibits K-Ras-induced
lung ADC as effectively as p53, we next compared the molec-
ular mechanisms involved in these tumor-suppressor genes’
activities. The results described above also suggest that the
inactivation of Runx3 occurs at an early stage of lung adeno-
carcinoma development. Arf and p21 play essential roles in
the p53-mediated cellular defense against oncogenic insult
(Levine, 1997; Kruse and Gu, 2009), and both genes are targets
of Runx proteins (Chi et al., 2005; Linggi et al., 2002). To
determine whether Runx3 is involved in the oncogenic K-Ras-
induced expression of Arf and p21, we performed immunohis-
tochemistry (IHC) analysis on lung ADCs from Adeno-Cre-
infected Runx3f/f/K-RasLSL-G12D/+ mice. The results revealed
that the levels of Arf and p21 in the lung ADCs were markedly
lower than the levels in the surrounding tissues (Figure 4A),
suggesting that Runx3 is required for the expression of Arf
and p21.
To gain insight into the mechanisms by which RUNX3 func-
tions as a gatekeeper, we needed to study the role of RUNX3
in an experimental system that allowed us to examine cell-cycle
control as well as uncontrolled cell growth. To this end, we
analyzed the events following the serum stimulation of HEK293
cells, which are sensitive to oncogenic K-RAS-induced
apoptosis (Chi et al., 2009). Using this cell line, we confirmed
that ARF and p21 were induced by oncogenic K-RAS and that
the inductions were disrupted by siRNA-mediated knockdown
of RUNX3 (Figure 4B). We cultured HEK293 cells in serum-free
conditions for 24 hr, and then stimulated them with serum for
1–8 hr. Northern blot analysis revealed that both p21 and ARF
were induced 1 hr after serum stimulation; their expression
peaked after 2 hr and returned to basal levels after 4 hr (Fig-
ure 4C). In contrast, p53 mRNA levels were not affected by
serum stimulation (Figure 4C). Immunoblot (IB) analysis also
showed that ARF and p21 were induced 1 hr after serum stimu-
lation and returned to basal levels after 8 hr (Figure 4D). During
the same interval, p53 protein expression was also transiently
increased (Figure 4D). Together, these results suggest thatnfected K-RasLSL-G12D/+ mouse lung.
ed images of the boxed regions are shown on the right.
f lung ADCs in Adeno-Cre-infected Runx3f/f/K-RasLSL-G12D/+ mice (2 months
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Figure 3. Dysregulation of RUNX3 Expression in Human Lung ADCs
(A) Human primary lung ADCs (20 samples each of K-RAS-mutated, EGFR-
mutated, and K-RAS/EGFR-nonmutated tumors) were analyzed by immuno-
staining with an anti-RUNX3 antibody. The inactivation frequencies of RUNX3
and p53 in each group are shown. Eight of the 60 ADCs with normal RUNX3
expression in the nucleus were all from the K-RAS/EGFR-nonmutated group.
The remaining 52 samples exhibited loss of RUNX3 expression.
(B) Representative images of RUNX3 expression in lung ADCs. Numbers in
parentheses indicate the patient numbers shown in Figure S3B.
See also Figure S3.
Cancer Cell
Runx3 Suppresses K-Ras-Induced Lung Cancer
608 Cancer Cell 24, 603–616, November 11, 2013 ª2013 Elsevier IncARF and p21 expression levels rise transiently early after serum
stimulation via transcriptional activation, whereas p53 levels rise
due to protein stabilization.
siRNA-mediated knockdown of RUNX3 abolished the serum-
stimulated induction of ARF and p21 (Figure 4D). Because p53
stabilization is mediated by the ARF-MDM2 pathway, the loss
of ARF induction also inhibited the serum-induced increase in
p53 protein (Figure 4D). In contrast, knockdown of p53 did not
affect the serum-stimulated induction of p21 (see below), con-
sistent with a previous report that the serum-stimulated induc-
tion of p21 is p53-independent (Michieli et al., 1994). These
results suggest that RUNX3 plays a key role in serum-stimulated
induction of ARF and p21, but that this function does not depend
on p53.
BRD2 Interacts with Acetylated RUNX3 and Contributes
to ARF and p21 Expression
To understand how RUNX3 regulates serum-stimulated induc-
tion of ARF and p21, we performed a large-scale functional
genetic screen of a fly mutant library and identified fs(1)h as a
modifier of lz, the fly ortholog of RUNX3 (Figures S4A–S4F).
The mammalian orthologs of fs(1)h are members of the bromo-
domain (BRD) family. One of these proteins, BRD2, is translo-
cated from cytoplasm to nucleus upon mitogenic stimulation
(Guo et al., 2000). Therefore, we investigated the role of BRD2
in RUNX3-induced ARF and p21 expression. Knockdown of
BRD2 abolished serum-stimulated induction of ARF and p21
(Figure 4E), indicating that both BRD2 and RUNX3 are involved
in serum-stimulated induction of these proteins.
To determine whether RUNX3 physically interacts with
BRD2, we performed immunoprecipitation (IP) and IB analyses,
which revealed that RUNX3 interacts weakly with BRD2 (Fig-
ure 4F). Because the bromodomain binds to acetylated lysine,
and RUNX3 is acetylated by p300 (Jin et al., 2004), we also
investigated the effect of p300 on the BRD2-RUNX3 inter-
action. Elevated expression of p300 increased the level of
RUNX3 acetylation and also reinforced the RUNX3-BRD2
interaction (Figure 4F). Arginine (R) substitution mutation
of the six lysine (K) residues in and adjacent to the Runt domain
of RUNX3 (Myc-RX3-6KR) abolished the RUNX3-BRD2 inter-
action (Figure S4G). By generating a series of mutant
constructs in which each of the mutated K residues from
Myc-RX3-6KR were restored individually, we identified K-94
and K-171 of RUNX3 as essential for the interaction of
RUNX3 with BRD2 (Figure 4G). Mapping of interaction domains
revealed that BRD2 interacts with RUNX3 via the first bromo-
domain (BD1; Figure S4H). Overall, these results suggest that
BD1 of BRD2 recognizes acetylated K-94 and K-171 of
RUNX3 and that p300 promotes the acetylation of these
residues.
RUNX3-BRD2 Complex Contributes to Serum-
Stimulated Induction of ARF and p21
To determine whether the RUNX3-BRD2 interaction is regu-
lated by serum stimulation, we monitored interactions between
endogenous RUNX3, BRD2, and p300 as a function of time in
HEK293 cells. IP and IB analyses revealed that the RUNX3-
p300 complex is formed 1 hr after serum stimulation; levels of
the complex peaked after 2 hr, and the complex had fully.
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Figure 4. RUNX3 and BRD2 Cooperate to
Induce ARF and p21
(A) IHC staining of Runx3f/f/K-RasLSL-G12D/+ mice
lungs (2 months after infection) with anti-Arf and
anti-p21 antibodies. Boxed regions are magnified
on the right.
(B) HEK293 cells were transfected with K-RasG12D
and control (con) or RUNX3-specific siRNAs.
Expression levels of RUNX3, K-RAS, ARF, and p21
were measured by IB.
(C) HEK293 cells were serum starved for 24 hr and
then stimulated with serum. The time-dependent
expression ofARF, p21, and p53wasmeasured by
Northern blotting. GAPDH was included as a
control.
(D and E) HEK293 cells were treated with control,
RUNX3-specific (RX3) (D), or BRD2-specific (E)
siRNA, serum starved for 24 hr, and then stimu-
lated with serum for the indicated times. Time-
dependent expression of ARF, p21, and p53 was
measured by IB.
(F) HA-p300 acetyltransferase, Flag-BRD2, and
Myc-RUNX3 were expressed in HEK293 cells, and
the effect of p300 on the BRD2-RUNX3 interaction
was measured by IP and IB.
(G) RX3-6KR was constructed by mutating the
lysine (K) residues within the Runt domain to
arginine (R). Each mutated lysine was then
individually mutated back to lysine (for example,
RX3-5KR-K94 contains five K-to-R mutations, but
residue 94 is K as in the wild-type protein). Various
K-to-R mutants of Myc-RUNX3 were co-
expressed with Flag-BRD2 and analyzed by IP and
IB. RX3, RUNX3; Tub, tubulin-1 (IB control); WT,
wild-type.
See also Figure S4.
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of RUNX3 and formation of the RUNX3-BRD2 complex also
rose during this interval: both events peaked after 2 hr of stim-
ulation and declined after 4 hr (Figure 5A). These results
suggest that serum stimulation activates p300-mediated acety-
lation of RUNX3, which leads to formation of the RUNX3-BRD2
complex.
To confirm the time-dependent association and dissociation
of the RUNX3-BRD2 complex after serum stimulation, we
transfected HeLa cells with Myc-RUNX3 and Flag-BRD2, and
examined the subcellular localizations of the expressed
proteins by immunofluorescence staining. Prior to serum stim-
ulation, RUNX3 and BRD2 were localized to the nucleus and
cytoplasm, respectively (Figure S5A). After 1–2 hr of serum
stimulation, BRD2 was colocalized with RUNX3 in the nucleus.
After 4 hr, BRD2 no longer co-localized with RUNX3
(Figure S5A).Cancer Cell 24, 603–616, NOverexpression of mutated RUNX3 in
which K-94 and K-171 were replaced
with R (Myc-RUNX3-KR-94-171) abol-
ished the RUNX3-BRD2 interaction and
p21 and ARF induction, suggesting that
the mutant has dominant-negative effect
(Figure 5B). Similarly, overexpression of
Flag-BRD2-DBD1, which also abolishesthe RUNX3-BRD2 interaction, also prevented p21 and ARF in-
duction (Figure 5C). These results suggest that the RUNX3-
BRD2 complex induces expression of ARF and p21.
Cyclin D1 Converts the RUNX3-BRD2 Complex into the
RUNX3-HDAC4 Complex
Cyclin D1 was induced 4 hr after serum stimulation and sub-
sequently bound to RUNX3 (Figure 5A). At the same time,
RUNX3 interacted with histone deacetylase 4 (HDAC4), result-
ing in deacetylation of RUNX3 (Jin et al., 2004), and RUNX3
was released from both p300 and BRD2 (Figure 5A). Specific
siRNA-mediated knockdown of Cyclin D1 inhibited deacety-
lation of RUNX3 and dissociation of the RUNX3-BRD2
complex, and maintained the expression of ARF and p21 until
8 hr after serum stimulation (Figure 5D). Expression of a
fixed amount of Myc-RUNX3 and HA-p300, along with
serially increasing amounts of HA-Cyclin D1 in HEK293 cells,ovember 11, 2013 ª2013 Elsevier Inc. 609
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Figure 5. The RUNX3-BRD2 Complex In-
duces ARF and p21
(A) HEK293 cells were serum starved for 24 hr, and
then stimulated with 10% serum. Cells were
harvested at the indicated time points. Time-
dependent formation of the BRD2-RUNX3, p300-
RUNX3, HDAC4-RUNX3, and Cyclin D1-RUNX3
complexes was measured by IP and IB.
(B) HEK293 cells were transfected with Flag-BRD2
and eitherMyc-RX3 orMyc-RX3-KR-94-171. Cells
were serum starved for 24 hr, and then stimulated
with 10% serum. Cells were harvested at the
indicated time points, and expression levels of the
BRD2-RUNX3 complex, ARF, p21, and p53 were
measured by IP and/or IB.
(C) HEK293 cells were transfected with Myc-RX3
and either Flag-BRD2 or Flag-BRD2-DBD1. Cells
were serum starved for 24 hr, and then stimulated
with 10% serum. Cells were harvested at the
indicated time points, and expression levels of the
RUNX3-BRD2 complex, ARF, p21, and p53 were
measured by IP and/or IB.
(D) HEK293 cells were transfected with control
(Con) or Cyclin D1-specific siRNA. Expression
levels of the RUNX3-BRD2 complex, RUNX3-p300
complex, Cyclin D1, ARF, and p21 were measured
by IP and/or IB at the indicated times after serum
stimulation.
(E) HEK293 cells were transfected with a fixed
amount of Myc-RX3 or HA-p300 and increasing
amounts of HA-Cyclin D1 (as indicated). The
RUNX3-Cyclin D1, RUNX3-p300, and RUNX3-
HDAC4 interactions were measured by IP and IB.
RX3, RUNX3; Ac-RX3, acetylated RUNX3; Tub,
tubulin-1 (IB control). See also Figure S5.
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RUNX3 and promoted the RUNX3-HDAC4 interaction in a
dose-dependent manner (Figure 5E). RUNX3 also interacted
with HDAC5, but Cyclin D1 did not affect this interaction
(Figure 5E).
These results suggest that Cyclin D1 displaces p300 from
RUNX3 and recruits HDAC4, leading to deacetylation of
RUNX3 and the subsequent release of BRD2. In other words,
Cyclin D1 destroys the RUNX3-BRD2 complex and mediates
the formation of an alternative RUNX3-HDAC4 complex, which
switches off ARF and p21 expression. These results demon-
strate a molecular mechanism for control of ARF and p21
expression in response to serum stimulation. The molecular
events involved in the formation of the RUNX3-BRD2 complex
and its conversion into the RUNX3-HDAC4 complex are summa-
rized in Figure S5B.610 Cancer Cell 24, 603–616, November 11, 2013 ª2013 Elsevier Inc.The RUNX3-BRD2 Complex Is
Responsible for Oncogenic K-RAS-
Induced Expression of p21 and ARF
To investigate whether the mechanism of
ARF and p21 induction by oncogenic K-
RAS was similar to that of serum stimula-
tion, we performed IP and IB analyses of
HEK293 cells transfected with either a
control vector orMyc-K-RasG12V. Expres-
sion of K-RasG12V triggered the formationof the RUNX3-BRD2 complex, which was maintained over the
8 hr observation period (Figure 6A). Consistent with this result,
the RUNX3-p300 interaction and RUNX3 acetylation were also
increased and maintained in cells expressing K-RasG12V (Fig-
ure 6A). By contrast, the RUNX3-Cyclin D1 and RUNX3-
HDAC4 interactions, which occurred 4 hr after serum stimulation
in control cells, were markedly reduced in cells expressing K-
RasG12V (Figure 6A). These results were consistent with those
obtained by expression of MEK-CA1 (Figure S6), suggesting
that destruction of the RUNX3-BRD2 complex requires not
only the induction of Cyclin D1, but also downregulation of the
K-RAS-MEK1 pathway, and that the maintenance of the
RUNX3-BRD2 complex is due to the persistence of K-RAS-
MEK1 pathway activity.
In control cells, p21 and ARF were induced 1–2 hr after serum
stimulation and quickly decreased to basal levels after 4 hr.
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Figure 6. K-Ras Induces ARF and p21 by
Maintaining the RUNX3-BRD2 Complex
(A) HEK293 cells transfected with empty vector
or Myc-K-RasG12V were serum starved for 24 hr,
and then stimulated with 10% serum. Cells
were harvested at the indicated times, and
the expression levels of Cyclin D1, p21, ARF,
and p53 were measured by IB. The RUNX3-
BRD2, RUNX3-p300, RUNX3-HDAC4, and
RUNX3-Cyclin D1 interactions were measured by
IP and IB.
(B–D) HEK293 cells were transfected with empty
vector or K-RasG12D, and control, RUNX3-spe-
cific, BRD2-specific, or p53-specific siRNA.
Expression levels of p21, ARF, and p53 were
measured by IB.
(E) HEK293 cells were transfected with Flag-BRD2
and Myc-RX3 (or Myc-RX3-KR-94-171) or Myc-
K-RasG12V (or MEK1-CA). Cells were serum
starved for 24 hr, and then stimulated with 10%
serum for 8 hr. Expression levels of ARF and p21,
phosphorylation of ERK (p-ERK), and the
RUNX3-BRD2 interaction were measured by IP
and/or IB.
RX3, RUNX3; Ac-RX3, acetylated RUNX3; and
Tub, tubulin-1 (IB control). See also Figure S6.
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Runx3 Suppresses K-Ras-Induced Lung CancerHowever, in cells expressing Myc-K-RasG12V, ARF and p21
levels were maintained during the 8 hr observation period (Fig-
ure 6A). These results suggest that constitutive activation of
oncogenic K-RAS pathway activity inhibits the RUNX3-Cyclin
D1 interaction, thereby preventing conversion of the RUNX3-
BRD2 complex into the RUNX3-HDAC4 complex. As a result,
the RUNX3-BRD2 complex is maintained and prolongs the in-
duction of ARF and p21.
Myc-K-RasG12V-induced ARF and p21 expression was
markedly reduced by knockdown of either RUNX3 (Figure 6B)
or BRD2 (Figure 6C), but not by knockdown of p53 (Figure 6D).
To further confirm that the RUNX3-BRD2 complex is responsible
for oncogenic Ras-induced expression of ARF and p21, we
transfected HEK293 cells with fixed amounts of Flag-BRD2
and either Myc-RUNX3 or Myc-RUNX3-KR-94-171 and serially
increasing amounts of either K-RasG12V or MEK1-CA. Cells
were serum starved for 24 hr and then serum-stimulated forCancer Cell 24, 603–616, N8 hr. IB and IP analyses of Myc-RUNX3-
expressing cells revealed that K-RasG12V
and MEK1-CA maintained the BRD2-
RUNX3 interaction and expression of
p21 and ARF (Figure 6E). In contrast,
K-RasG12V andMEK1-CA failed to induce
ARF and p21 in cells expressing
Myc-RUNX3-KR-94-171, which are
unable to form the RUNX3-BRD2
complex (Figure 6E). These results sug-
gest that oncogenic K-Ras maintains the
RUNX3-BRD2 complex via the MEK1
pathway and that the RUNX3-BRD2
complex is responsible for prolonged
expression of ARF and p21. Moreover,
the induction of ARF and p21 by onco-genic K-Ras is an extension of the transient induction of these
genes by serum stimulation.
RUNX3-BRD2 Complex Formation in K-RAS-Activated
Human Non-Small-Cell Lung Cancer Cell Lines
We next examined whether the RUNX3-BRD2 complex could be
formed and maintained by endogenous oncogenic K-RAS in
lung cancer cell lines. For this purpose, we obtained two human
non-small-cell lung cancer cell lines, A549 (RUNX3-normal, ARF
null and p53-wild-type) and H460 (RUNX3-inactivated, ARF-
wild-type and p53-wild-type), both of which have oncogenic
K-RASmutations (Mallakin et al., 2007). Most of K-RASmutated
human non-small-cell lung cancer cell lines tested also have
mutation in either ARF or p53, except H460. A549 cells were
serum starved, stimulated with serum, and then the interaction
of the endogenous RUNX3 and BRD2 was monitored. Notably,
RUNX3-BRD2 complex was formed and stably maintained dueovember 11, 2013 ª2013 Elsevier Inc. 611
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Figure 7. Oncogenic K-RAS Induces
RUNX3-BRD2 Complex Formation, which
Induces p21, ARF, and p53 in Human Non-
Small-Cell Lung Cancer Cell Lines
(A) A549 cells were serum starved for 24 hr, and
then stimulated with 10% serum. Cells were har-
vested at the indicated times, and the expression
levels of Cyclin D1 and RUNX3 were measured by
IB. The RUNX3-BRD2 interaction was measured
by IP and IB.
(B and C) A549 cells (B) and H460 cells (C) trans-
fected with empty vector, Myc-RUNX3, or Myc-
RX3-KR-94-171 were serum starved for 24 hr, and
then stimulated with 10% serum. Cells were har-
vested at the indicated times, and the expression
levels of Cyclin D1, p21, ARF, and p53 were
measured by IB. The RUNX3-BRD2 interaction
was measured by IP and IB.
(D) H460 cells were transfected as above and
stained with Annexin V-FITC. Apoptotic cells were
depicted under a fluorescence microscope.
(E) H460 cells were transfected as above, and
apoptotic cells were detected by flow cytometry
after Annexin V-FITC and PI labeling. The abscissa
and ordinate represent the fluorescence intensity
of Annexin V-FITC and PI, respectively. The per-
centages of early apoptotic cells (Annexin V-FITC
positive/PI negative; lower right quadrant) and late
apoptotic or necrotic cells (Annexin V-FITC posi-
tive/PI positive; upper right quadrant) are shown.
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Runx3 Suppresses K-Ras-Induced Lung Cancerto the endogenous oncogenic K-Ras (Figure 7A). Exogenously
expressed RUNX3 also interacted with BRD2 and increased
the level of p21 (Figure 7B). But the level of p53 was not
increased by the expression of RUNX3 most likely due to the
absence of ARF (Figure 7B).
We then, analyzed H460 cell line, which expresses little or no
RUNX3 or ARF, p21, and p53 (Somasundaram and El-Deiry,
1997; Li et al., 2004). We hypothesized that the failure of onco-
genic K-RAS-induced expression of the three tumor-suppressor
genes in this cell line might be due to the lack of RUNX3 expres-
sion. To test this possibility, we transfected the cells with empty
vector, Myc-RUNX3, or Myc-RUNX3-KR-94-171, stimulated
them with serum, and then monitored the RUNX3-BRD2 interac-
tion and expression levels of ARF, p21, and p53. Importantly,
expression of RUNX3 resulted in formation of a stable RUNX3-
BRD2 complex and expression of ARF, p21, and p53 (Figure 7C).
However, expression of RUNX3-KR-94-171 failed to induce the
three tumor-suppressor genes (Figure 7C). These results sug-
gest that endogenous oncogenic K-RAS could inhibit Cyclin
D1-mediated dissociation of the RUNX3-BRD2 complex and
the complex is essential for the oncogenic K-RAS-induced
expression of themajor tumor-suppressor genes in the lung can-
cer cell lines.612 Cancer Cell 24, 603–616, November 11, 2013 ª2013 Elsevier Inc.We then analyzed whether exogenous
expression of RUNX3 could evoke onco-
gene-induced apoptosis. H460 cells
were transfected with empty vector,
Myc-RUNX3, or Myc-RUNX3-KR-94-
171, and then stained with Annexin V-
fluorescein isothiocyanate (FITC). A largeproportion of RUNX3-transfected cells were Annexin V-positive,
whereas very few vector- or Myc-RUNX3-KR-94-171-trans-
fected cells were Annexin V-positive (Figure 7D). Flow-cytomet-
ric analysis following Annexin V-FITC and propidium iodide (PI)
staining revealed that Myc-RUNX3 markedly increased
apoptotic cell death, whereas Myc-RUNX3-KR-94-171 had no
effect (Figure 7E). These results demonstrate that loss of
RUNX3 expression is a critical molecular event abrogating
cellular defenses against oncogene-induced tumor formation,
at least in some human non-small-cell lung cancer cell lines.
DISCUSSION
Inactivation of Runx3 Induces Lung AD and Greatly
Accelerates the K-Ras-Induced Development of ADC
K-Ras activation is an early event in the development of lung
ADC, and inactivation of p53 significantly accelerates tumor
development. However, restoration of p53 can destroy well-
developed lung ADC but not AD, and p53 does not prevent AD
formation (Feldser et al., 2010; Junttila et al., 2010). Thus, there
is an apparent gap in tumor suppression at the early stage of
the tumor development, in that a low level of oncogenic stimulus
that is sufficient to induce adenoma is not prevented by p53. In
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Figure 8. A Proposed Model for Cellular
System that Monitors Mitogenic Signal
Integrity and Defends against Oncogenic
Ras-Induced Tumor Formation
(A) Schematic illustration of the fluctuations in K-
Ras activity and expression levels of ARF, p21,
and Cyclin D1. Upon mitogenic stimulation, wild-
type (WT) K-Ras activity quickly increases, rea-
ches a peak, and then decreases again (green
line). Heterozygous oncogenic mutation of K-Ras
leads to constitutive maintenance of 50% of
maximum K-Ras activity (red line; left). In WT cells,
expression levels of ARF and p21 are decreased
when Cyclin D1 is induced (middle). In K-Ras-
activated cells, the expression levels of ARF and
p21 are stabilized due to the maintenance of 50%
of maximum K-Ras activity (right).
(B) Schematic illustration of the pathways. Purple
lines indicate the fast pathway, which is activated
immediately after mitogenic stimulation; this
pathway induces RUNX3-BRD2 complex forma-
tion and expression of p21 and ARF. Green lines
indicate the slow pathway, which induces Cyclin
D1 4 hr after mitogenic stimulation. A decrease in
K-Ras pathway activity and an increase in Cyclin D1 convert the RUNX3-BRD2 complex to a RUNX3-HDAC4 complex. As a result, the expression ofARF and p21
is switched off. When K-Ras is constitutively activated, the oncogenic Ras-activated MEK1 pathway inhibits conversion of the RUNX3-BRD2 complex into the
RUNX3-HDAC4 complex (red line). As a result, expression of ARF and p21 remains switched on.
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Runx3 Suppresses K-Ras-Induced Lung Cancerthis study, we show that inactivation of Runx3 induces lung AD
and accelerates K-Ras-induced development of ADC develop-
ment as effectively as loss of p53. These results demonstrate
the potent tumor-suppressor activity of Runx3 against onco-
genicK-Ras-induced lung ADCs. However, there is a remarkable
difference between p53 and Runx3: although p53 suppresses
tumor progression, it does not suppress tumor initiation (Feldser
et al., 2010; Junttila et al., 2010). In contrast, Runx3 appears to
suppress tumor initiation because Runx3 inactivation resulted
in lung ADs. In comparison, although Nkx2-1 significantly limits
oncogenic K-Ras-induced lung ADC, inactivation of the gene
by itself does not induce lung AD (Snyder et al., 2013; Winslow
et al., 2011). Therefore, the results presented in this article fill
the apparent gap in the cellular defenses against the initial stage
of adenoma formation.
Discrimination between Normal K-Ras and Oncogenic
K-Ras Activity
Transcriptional activation of ARF is essential for oncogenic RAS-
induced stabilization of p53, which plays major roles in tumor
suppression (Palmero et al., 1998; Efeyan and Serrano, 2007).
In addition, p21, which is induced in both p53-dependent and
-independent manners, also plays a key role in defense against
oncogenic RAS (Adnane et al., 2000; Borgdorff et al., 2010;
Kruse and Gu, 2009). However, the mechanism by which cells
sense oncogenic RAS and induce ARF to trigger the major
tumor-suppressor pathway remains unknown (Lowe and Sherr,
2003).
We show here that Runx3 exerts potent tumor-suppressor
activity, nearly equivalent to that of p53 reported previously (Du-
Page et al., 2009). In addition, ARF and p21 are the targets of
RUNX proteins: exogenous expression of RUNX proteins
increased the expression of both genes; regulatory regions of
both genes contain multiple RUNX binding sites; and ChIP as-Cansays have confirmed the binding of RUNX proteins within the
promoter regions (Chi et al., 2005; Linggi et al., 2002). These
results suggest that Runx3 may be involved in the major tu-
mor-suppressor pathway studied in connection with p53. p21
is transiently induced early after mitogenic stimulation in a p53-
independent manner (Michieli et al., 1994). Although ARF is not
periodically expressed during the cell cycle, its expression
soon after serum stimulation has not been analyzed (Aslanian
et al., 2004; Komori et al., 2005). Therefore, we analyzed the
influence of RUNX3 and RAS signaling on the expression of
ARF and p21 soon after mitogenic stimulation. Both p21 and
ARF were transiently induced by serum stimulation, and the in-
duction of both genes was dependent on both K-RAS activity
and RUNX3. The level of ARF induced by serum stimulation
was sufficient to stabilize p53. In normal cells, RAS activity
was temporarily activated soon after serum stimulation, but
then returned to basal levels; ARF and p21 expression follow
similar patterns. In the context of serum stimulation, ARF and
p21 do not inhibit the cell cycle because their expression is
switched off before the G1/S checkpoint. However, in oncogenic
K-RAS-expressing cells, K-RAS, activity wasmaintained and the
expression levels of ARF, p21, and p53 were sustained, allowing
them to inhibit cell-cycle progression (Figure 8A).
How, then, do cells recognize persistent oncogenic K-RAS
activity, leading to maintenance of ARF and p21 expression,
and what might be the role of RUNX3 in this process? We found
that K-RAS activation triggered the formation of a RUNX3-BRD2
complex that induced ARF and p21 expression 1–2 hr after stim-
ulation. When K-RAS activity was reduced and Cyclin D1 was
induced (4 hr after serum stimulation), the RUNX3-BRD2 com-
plex was converted into the RUNX3-HDAC4 complex, resulting
in inhibition ofARF and p21 expression.When K-Raswas consti-
tutively activated, however, the RUNX3-BRD2 complex was
maintained, along with ARF and p21 expression and p53cer Cell 24, 603–616, November 11, 2013 ª2013 Elsevier Inc. 613
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Runx3 Suppresses K-Ras-Induced Lung Cancerstabilization. Under such conditions, ARF, p21, and p53 could
inhibit cell-cycle progression and, even in the presence of
oncogenic K-RAS, the cell cycle would be regulated. However,
abrogation of the RUNX3-BRD2 complex formation abolished
oncogenic K-RAS-induced ARF and p21 expression, resulting
in deregulation of the cell cycle (Figure 8B). Therefore, themolec-
ular events involved in serum or RAS-stimulated induction of
ARF and p21 might be associated with the mechanism underly-
ing recognition of oncogenic K-RAS, which collapses when
RUNX3 is inactivated. These results effectively explain how cells
respond to persistent activation of oncogenic K-RAS, and why
inactivation of Runx3 accelerates oncogenic K-Ras-induced
lung tumorigenesis as effectively as inactivation of p53.
Restoration of RUNX3 in Lung Cancer-Derived Cell Line
Activates the ARF-p53 Pathway and Induces Apoptosis
If RUNX3-BRD2 complex plays a role in cellular defense mecha-
nism against oncogene activation, the complex should be
formed in response to endogenous oncogenic K-RAS and acti-
vate the ARF-p53 pathway in lung cancer-derived cell lines.
The results obtained in two K-RAS-mutated human non-small-
cell lung cancer-derived cell lines showed that this is indeed
the case. The lack of ARF-p53 pathway activation in these two
K-RAS activated cell lines appears to be due to the absence of
ARF (A549) or RUNX3 (H460). Restoration of RUNX3 led to the
induction of ARF, p53, and p21 in a RUNX3-BRD2 complex-
dependent manner, and the cells subsequently underwent
apoptosis. If the relationship between RUNX3 and the ARF-
p53 pathway were to be firmly established, RUNX3 should
then be considered as an upstream regulator of the p53 tumor-
suppressor network. Future studies will address the generality
of this phenomenon among non-small-cell lung cancer-derived
cell lines.
RUNX3-BRD2Complex Is Required for the Expression of
p14ARF and p21
Our results show that RUNX3-BRD2 interaction is required for
induction of ARF and p21. BRD2 was identified as a close homo-
log of the basal transcription co-activator TAFII250 (Beck et al.,
1992). BRD2 participates in multiprotein transcription com-
plexes such as Mediator, recruits the SWI/SNF chromatin-
remodeling complex, and contributes to transcriptional control
(Denis et al., 2006). BRD2 binds to acetylated histones and
allows RNA polymerase II to transcribe through the nucleosome
in a defined transcription system (LeRoy et al., 2008). Interest-
ingly, RUNX1 physically interacts with multiple subunits of the
SWI/SNF complex and regulates its target genes, including
p21 and ARF (Bakshi et al., 2010). These results suggest that
RUNX3 may activate transcription as a part of a large protein
complex, in which the basal transcription complex and the chro-
matin remodeling complex are bridged by BRD2.
BRD family members contain two bromodomains (BDs) that
recognize acetylated lysines. The second BD (BD2) binds acety-
lated histone H4. We show that a DNA binding transcription fac-
tor, RUNX3, binds to BD1 of BRD2. Although BRD proteins also
interact with a number of non-histone proteins including other
transcription factors such as E2F1, none of the proteins are re-
ported to be recognized by the bromodomains. Therefore,
RUNX3 appears to be an exceptional transcription factor and614 Cancer Cell 24, 603–616, November 11, 2013 ª2013 Elsevier IncBRD2 could bind both RUNX3 and histone simultaneously at
its BD1 and BD2 domains, respectively.
Inactivation of RUNX3 Induces Two Distinct Types of
Lung ADs
Most tumors exhibit a diverse array of differentiation states
accompanied by dysregulation of lineage-specific transcription
factors, suggesting that deregulation of the differentiation
program is closely associated with tumor evolution. In humans,
multiple types of lung ADCs exist, including mucinous and non-
mucinous types, and about 75% of mucinous type lung ADCs
have K-RAS mutations (Subramanian and Govindan, 2008;
Travis et al., 2004). However, K-Ras activation in a mouse model
results in the development of only nonmucinous AD/ADC. Loss
of Nkx2-1, a master regulator of pulmonary differentiation, in-
duces mucinous ADC in combination with K-Ras activation
(Maeda et al., 2012; Snyder et al., 2013). Together, these results
suggest that to induce mucinous ADC, K-Ras activation alone is
not sufficient, and an additional event is required. We have
previously shown that RUNX3 plays a key role in lineage determi-
nation of lung epithelial cells, and is frequently inactivated in
human AAH/BAC (Lee et al., 2010). In this study, Runx3 inactiva-
tion in mouse lung resulted in the development of both mucinous
and nonmucinous lung ADs, and the tumors progressed into the
corresponding types of ADCs uponK-Ras activation. BothNkx2-
1 and Runx3 are involved in differentiation of lung cells, suggest-
ing that deregulation of the differentiation program might be
associated with the determination of tumor type.
Collectively, our results suggest that Runx3 inhibits lung ade-
noma formation and plays an important role in discriminating
normal K-Ras from oncogenic K-Ras, which is essential for the
cellular defense mechanism mediated by the ARF-p53 pathway.
These results provide a missing link between oncogenic K-Ras
and the p14ARF-p53 pathway and may fill the gap in current
knowledge regarding howcells defend against oncogenicK-Ras.
EXPERIMENTAL PROCEDURES
Mice
Runx3flox mice were kindly provided by Dr. I. Taniuchi (Naoe et al., 2007).
K-RasLSL-G12D knockin mice were obtained from Jackson Labs. Adeno-Cre
was purchased from Vector Biolabs. Runx3 was disrupted by intranasally in-
fecting mice with 2.5 3 107 PFU Adeno-Cre (DuPage et al., 2009). Animal
studies were approved by the Institutional Animal Care Committee of Chung-
buk National University.
Human Primary Tumor Samples
Paraffin-embedded tissue samples from patients that had undergone resec-
tions of primary lung cancer were obtained from Bundang Hospital at Seoul
National University. Human tissue samples were analyzed with prior approval
from the Institutional Ethics Committee of Bundang Hospital of Seoul National
University and informed consents have been obtained.
Histology and Immunohistochemistry
IHC was performed as described previously (Lee et al., 2010). Anti-SP-C, anti-
CC10, anti-Sox2, anti-p21, anti-p19ARF, and anti-PCNA (Santa Cruz Biotech-
nology) were used as the primary antibodies. Alexa Fluor 647, Alexa Fluor 594,
and Alexa Fluor 488-conjugated antibodies (Invitrogen) were used as the sec-
ondary antibodies. Stained tissues were depicted with a conventional micro-
scope mounted with a DP71 digital camera (Olympus) or an LSM 710
T-PMT confocal microscope (Carl Zeiss). Images were processed with equiv-
alent parameters using the ZEN Light Edition software (Carl Zeiss)..
Cancer Cell
Runx3 Suppresses K-Ras-Induced Lung CancerPlasmids and siRNAs
Full-lengthBRD2 and its deletionmutants were engineered by PCR and cloned
into the pCS4-3Flag or pCS4-3Myc vector. Full-length RUNX3 and its deletion
and lysine mutants were constructed similarly. siRNAs corresponding to
RUNX3, BRD2, and TP53 were purchased from Bioneer (Daejeon).
Cell Culture and Transfection
HEK293, A549 and H460 were obtained from Korean Research Institute of
Bioscience and Biotechnology (KRIBB). Transient transfection was performed
using the Lipofectamine Plus reagent (Invitrogen). Apoptotic cell death was
measured by Annexin V-FITC Apoptosis Detection Kit I (BD Bioscience).
Antibodies
Antibodies targeting c-Myc, Cyclin D1, p14ARF, p21, p53, p300, HDAC4, and
HDAC5 were obtained from Santa Cruz Biotechnology. Antibodies targeting
p-ERK, MEK1, and acetylated lysine were obtained from Cell Signaling Tech-
nology. Antibodies targeting HA (12CA5; Roche), FLAG (M2; Sigma), Myc
(9E10; Santa Cruz Biotechnology), Ras (Oncogene), BRD2 (M01; Abnova),
and RUNX3 (5G4; Abcam) were used for IB and IP.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.10.003.
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